Reneuron Stem Cell Retinitis Pigmentosa

Clinical development of hrpc for retinitis pigmentosa a blindness causing disease of the retina is progressing in the us and we have the.

Reneuron stem cell retinitis pigmentosa.

Reneuron group plc aim. We have worked with world leading collaborators and academic institutions in the retinal disease field to successfully take our retinitis pigmentosa programme through pre clinical development. Reneuron upbeat on retinitis pigmentosa therapy development. Pre clinical studies carried out in disease models by the our academic collaborators have demonstrated that when transplanted into the retina our hrpc technology has the potential to preserve existing photoreceptors.

Our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need. Rp is a group of hereditary. About reneuron we are a leading clinical stage stem cell business. Rene a global leader in the development of cell based therapeutics is pleased to announce positive long term data from the ongoing phase 1 2a clinical trial of its hrpc stem cell therapy candidate in retinitis pigmentosa rp and plans to expand the ongoing study.

Thu 10 september 2020 16 00 a a a. Cell based therapeutics developer reneuron group updated the market. Retinitis pigmentosa is a group of hereditary diseases of the eye that lead to progressive loss of vision due to cells in the retina becoming damaged and eventually dying. Our hrpc stem cell therapy candidate for rp benefits from orphan drug designation in both europe and the us.